Common adverse reactions included nausea, diarrhea, and vomiting.172 GSBR-1290 GSBR-1290 is an oral small molecule GLP-1RA developed by Structure Therapeutics, aimed at treating T2DM and obesity
1.3% of people taking Wegovy in trials had hypotension compared to .4% on placebo
Zepbound (Tirzepatide for Weight Management) Zepbound contains the same active ingredient as Mounjaro (tirzepatide), but its branded and approved specifically for chronic weight management
We specialize in personalized pharmaceutical care, offering compounding services and customized medications tailored to your unique needs
The honest answer is that it depends on the individual
From a metabolic standpoint, glycemic control may worsen, particularly in patients with type 2 diabetes